Trials / Terminated
TerminatedNCT00234468
Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC
A Phase III, Double-Blind, Randomised Study Comparing ZD1839 (IressaTM) Versus Placebo As Maintenance Therapy In Subjects With Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) After Combined Modality Therapy
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 490 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study if to determine if Iressa can prolong the period of time without any disease worsening (Time to progression) in patients previously treated with combined therapy such as surgery and chemotherapy with or without radiotherapy or chemotherapy and radiotherapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Iressa (Gefitinib) |
Timeline
- Start date
- 2004-01-01
- Completion
- 2007-08-01
- First posted
- 2005-10-07
- Last updated
- 2011-05-20
Locations
32 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT00234468. Inclusion in this directory is not an endorsement.